Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with
http://www.100md.com
《血液学杂志》
the Sanofi-Synthelabo Recherche, Toulouse, France
Department of Medicine, St George Hospital, Kogarah, Australia
Department of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany
Service d'Hematologie-Hemostase, hospital Trousseau, Tours, France
Platelet Immunology Laboratory, McMaster University, Hamilton, ON, Canada
NV Organon, Oss, The Netherlands.
Abstract
Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy caused by antibodies against a complex of platelet factor 4 and heparin. Fondaparinux (Arixtra) is a new synthetic selective factor Xa inhibitor. We performed a serologic study to determine the cross-reactivity of HIT sera with fondaparinux. Using a prospective, blinded study design, 39 clinically and serologically confirmed sera from patients with HIT and 15 control sera were sent to 3 different laboratories, each of which specialized in a particular HIT assay. These include the serotonin release assay, heparin-induced platelet agglutination assay, and platelet aggregation assay. Two of 82 assays (2.4%) performed in the presence of control sera were positive, both with unfractionated heparin. In the presence of HIT sera, 75 of 94 (79.8%) evaluable assays were positive with unfractionated heparin; fondaparinux was significantly (P < .001) less reactive than unfractionated heparin, only 3 of 91 evaluable assays (3.3%) being positive. Using flow cytometry, unlike unfractionated heparin, fondaparinux did not induce the binding of PAC1 and anti-CD62 monoclonal antibodies or of annexin V to platelets with HIT sera. Together, these results suggest that fondaparinux is nonreactive to HIT sera and raise the possibility that the drug may be used for prophylaxis and treatment of thrombosis in patients with a history of HIT.
Introduction
Heparin-induced thrombocytopenia (HIT) is a rare but severe complication of heparin therapy.1 HIT is caused by heparin-dependent antibodies (typically IgG), which are directed against a molecular complex formed by heparin and the platelet -granule protein, platelet factor 4.1 These IgG immune complexes bind to the FcIIa receptors on the platelet surface, resulting in platelet activation and aggregation, and eventually, to the occurrence of both thrombocytopenia and thrombosis. For patients with HIT, treatment with heparin must be stopped and an alternative antithrombotic agent used. Low-molecular-weight heparins cannot be used because they also cross-react, although to a lesser extent, with HIT-associated antibodies.1
Fondaparinux, a new synthetic and selective inhibitor of coagulation factor Xa,2,3 has been shown to be an effective and safe antithrombotic agent in a number of thrombotic disorders.4-13 No episodes of HIT were reported in the large phase 2 and 3 clinical program. This result is consistent with the fact that, in vitro, fondaparinux did not cross-react with HIT-associated antibodies.14-17 However, these in vitro studies, using a limited set of sera and different methodologies of variable sensitivity and specificity, did not permit a definitive conclusion to be made regarding the safety of fondaparinux in terms of its ability to induce platelet activation in the presence of HIT-associated antibodies.
Currently, besides enzyme immunoassays that measure antibodies to heparin-platelet factor 4 complex, 3 functional assays are used in vitro to investigate the effect of HIT-associated antibodies on platelet function, namely, the serotonin release assay (SRA), considered to be the gold standard,18 the heparin-induced platelet agglutination assay (HIPA),19 and the platelet aggregation test.20 These biologic assays are difficult to perform and interpret.1,21 Additionally, there may be advantages in performing all assays together to further enhance sensitivity and specificity.21 Using these 3 assays, we compared in a blinded manner the effect of fondaparinux with that of unfractionated heparin on platelet activation and aggregation in the presence of sera collected from patients with clinically documented HIT. The effect of fondaparinux on platelet activation in the presence of HIT sera was further assessed using sensitive flow cytometry techniques to measure the expression of specific platelet activation-related markers on the platelet surface.22-24
Patients, materials, and methods
Study design
Sera from patients with laboratory-confirmed HIT (HIT sera) and from subjects without HIT (control sera) were collected in 3 centers (see "Appendix"). All the sera were then aliquoted and a subsample sent to a predetermined reference laboratory (see "Appendix") for characterization. This reference laboratory performed both enzyme immunoassays plus SRA on all of these samples to confirm positive or negative results. These independently verified sera were then sent to the central laboratory. The central laboratory then sent out the positive HIT sera and negative control sera, in a coded and blinded fashion, to the 3 participating test laboratories (see "Appendix"). All of the 3 test laboratories were also provided with solutions of buffer, unfractionated heparin, and fondaparinux for the serotonin release, platelet agglutination, and platelet aggregation assays. One specific assay was performed per center. All investigators were blinded about the type of serum and the type of test solution. All blood donors gave informed consent in accordance with the Declaration of Helsinki.
Sera
A first set of sera was obtained from 45 patients with a diagnosis of HIT. These patients had HIT defined by a fall in the platelet count to less than 100 x 109/L or a 50% decrease in platelet count, 5 or more days after starting heparin therapy. Other causes of thrombocytopenia (ie, autoimmune thrombocytopenia, secondary immune thrombocytopenia, drug-dependent thrombocytopenia, and infection-dependent thrombocytopenia) were excluded, according to clinical diagnosis. The HIT sera were all positive in the designated reference laboratory. A second set of sera was obtained from 15 healthy volunteers not receiving heparin or other agents known to affect the coagulation system. All sera collected from patients with HIT, positive on SRA, and confirmed to have antibodies against heparin-platelet factor 4 (HIT-IgG) by the reference laboratory, were categorized as "HIT serum." All sera collected from healthy subjects, negative on SRA and in which the absence of HIT-IgG was confirmed by the reference laboratory, were designated as "control serum." Before use, the sera were heated at 56°C for 30 minutes to inactivate complement and traces of thrombin. Except for confirmatory testing, the reference laboratory was not part of the laboratory testing.
Unfractionated heparin and fondaparinux
Solutions of various concentrations of unfractionated heparin (Sanofi-Synthelabo, Paris, France) and fondaparinux (Sanofi-Synthelabo, Toulouse, France, and Organon, Oss, The Netherlands) were prepared in saline and frozen until use. The final concentrations of unfractionated heparin and fondaparinux used in the different assays on platelet function were 0.1, 0.3, 1.0, and 100 IU/mL, and 0.1, 0.3, 1.0, 3.0, and 100 μg/mL, respectively.
Enzyme immunoassay for antibodies to heparin–platelet factor 4 complex
The presence of antibodies to heparin–platelet factor 4 complex (HIT-IgG) was investigated using an enzyme immunoassay described previously.25 Purified platelet factor 4 (20 μg/mL; R&D Systems, Lille, France) and unfractionated heparin (1 IU/mL; Organon Teknika, Toronto, ON, Canada) were incubated overnight at 4°C in carbonated buffer (50 mM NaHCO3/Na2CO3, pH 9.6) on a 96-well microtiter plate. The plate was then saturated with 10% normal goat serum (Santa Cruz Biotechnology, Heidelberg, Germany) in phosphate-buffered saline (PBS; pH 7.2) for 2 hours at room temperature. Test sera diluted in 2% normal goat serum in PBS were added, and the microtiter plate was incubated at room temperature for 1 hour. After washing, alkaline phosphatase-conjugated, goat Fc chain-specific antihuman IgG antibody (Jackson ImmunoResearch, West Grove, PA) was added to each well. After 1 hour of incubation and washing, p-nitrophenyl phosphate (1 mg/mL in diethanolamine buffer, 1 M, pH 9.6) was added, and the absorbance was read at 405 nm. The result was considered as positive when the optical density (OD) was more than 0.45.
Platelet activation assays for HIT-associated antibodies
SRA. The SRA was performed as previously described.18 Platelet-rich plasma, obtained by centrifugation (165g, 15 minutes) of whole blood collected in acid-citrate-dextrose (ACD; 1:6, vol/vol, pH 4.5) from healthy individuals who had not taken aspirin within the 7 days preceding blood collection, was incubated with 14C-serotonin (0.1 μCi [0.0037 MBq]/mL platelet-rich plasma; Amersham, Oakville, ON, Canada or Amersham, Little Chalfront, Buckinghamshire, United Kingdom) for 30 minutes at 37°C. Sera and solutions of buffer, unfractionated heparin, or fondaparinux were added to washed, radiolabeled platelets; the mixture was incubated with constant stirring or under gentle agitation at room temperature for 1 hour. The reaction was stopped by adding EDTA (ethylenediaminetetraacetic acid, 0.5%)/PBS buffer, and the amount of 14C-serotonin released into the supernatant was measured using a scintillation counter after centrifugation (1800g, 5 minutes). The result was considered as "positive" with unfractionated heparin when the release of 14C-serotonin was more than 20% at 0.1, 0.3, or 1 IU/mL unfractionated heparin and less than 20% at 100 IU/mL unfractionated heparin. For fondaparinux, a result was considered as "positive" when the release was more than 20% at 0.1, 0.3, 1.0, or 3.0 μg/mL fondaparinux and less than 20% at 100 μg/mL fondaparinux. If the release was more than 20% in the presence of buffer, 100 IU/mL unfractionated heparin, or 100 μg/mL fondaparinux, the result was considered as "indeterminate." In all other cases, the result was considered as "negative." The "positive" results obtained with SRA at 0.1 IU/mL and 0.3 IU/mL unfractionated heparin were only considered true positive if they could be confirmed by suppression with anti-FcIIa receptor antibodies (10 μg/mL, American Type Culture Collection, Rockville, MD).
HIPA. HIPA was performed as previously described.26 Platelet-rich plasma was prepared by centrifugation (120g, 20 minutes) from citrated blood (ACD; 1.6:8.4, vol/vol) from healthy donors who had not taken any medication within the previous 10 days. Apyrase (grade IV, 5 μL at 1000 U/mL; Sigma, Munich, Germany) was added, and platelets were washed and resuspended in Tyrode buffer (pH 6.3) containing 2.5 U/mL apyrase and 1 U/mL hirudin (Pentapharm, Basel, Switzerland). After incubation in sealed tubes at 37°C for 15 minutes, platelets were centrifuged (650g, 7 minutes), resuspended to obtain a platelet concentration of 300 to 400 x 109/L in 1 mL suspension buffer (Tyrode buffer, 0.212 M MgCl2, 0.196 M CaCl2, pH 7.2), and incubated in a sealed tube at 37°C for 45 minutes before use. Sera (20 μL), solutions of buffer, unfractionated heparin or fondaparinux (10 μL), and platelet suspension (75 μL) were dispensed into a microtiter plate that contained 2 steel spheres, and further incubated at room temperature on a magnetic stirrer for 45 minutes. The transparency of the solution was assessed every 5 minutes using an indirect light source. Duplicate experiments were performed for each platelet suspension. Each serum was tested with platelets from 4 different platelet donors. For unfractionated heparin, the result was considered as "positive" if the suspension became transparent due to platelet agglutination with 0.1, 0.3, or 1 IU/mL unfractionated heparin, but not or only weakly and with a significant delay with buffer and 100 IU/mL unfractionated heparin, for at least 2 of the 4 platelet donors. For fondaparinux, the result was "positive" if the suspension became transparent with 0.1, 0.3, 1.0, or 3.0 μg/mL fondaparinux, for at least 2 of the 4 platelet donors. If platelet agglutination occurred in the presence of 100 IU/mL unfractionated heparin for at least 2 of the 4 platelet donors, the result was considered as "indeterminate." In all other cases, the result was considered as "negative."
Platelet aggregation. Platelet aggregation was performed as previously described.27 Platelet-rich plasma, obtained by centrifugation (150g, 10 minutes) of whole blood collected in citrate (0.129 M, 1:9, vol/vol) from healthy individuals who had not taken aspirin within the 7 days preceding blood collection, was adjusted to 300 x 109/L. Platelet aggregation was measured at 37°C using an aggregometer (Platelet Aggregation Profiler; BioData, Horsham, PA). The ability of donor platelets to aggregate was first tested in the presence of collagen (70 μg/mL, Stago, Asnières, France). Then, platelet-rich plasma was incubated with sera and solutions of buffer, unfractionated heparin, or fondaparinux. Aggregation was considered as "positive" when it exhibited a sharp initial slope ( 20%/min) and a maximum level of aggregation of 50% or more within 20 minutes. For unfractionated heparin, the result was considered as "positive" when platelet aggregation occurred with 0.1, 0.3, or 1 IU/mL unfractionated heparin, but not with 100 IU/mL unfractionated heparin. For fondaparinux, the result was "positive" when platelet aggregation occurred at 0.1, 0.3, 1.0, or 3.0 μg/mL fondaparinux, but not with 100 μg/mL fondaparinux. If platelet aggregation occurred in the presence of buffer, 100 IU/mL unfractionated heparin, or 100 μg/mL fondaparinux, the result was considered as "indeterminate." In all other cases, the result was considered as "negative," but before concluding the result was negative, platelet-rich plasma from at least 2 different donors was tested.
Flow cytometry analysis
Platelet-rich plasma was prepared by centrifugation (100g, 5 minutes) from citrated blood (citrate 0.129 M, 1:9, vol/vol) from healthy individuals to which was added 180 μL acidifying buffer/1 mL platelet-rich plasma. Acidifying buffer contained 75 mM trisodium citrate dehydrate, 38 mM citric acid monohydrate, 140 mM dextrose, and prostacyclin (12 ng/mL final, Sigma). Platelets were washed and resuspended in HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer containing 134 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.34 mM Na2PHO4, 1 mM MgCl2, 5 mM glucose, 5 mM HEPES, and 0.35% bovine serum albumin (pH 7.4). Platelet suspension samples (140 μL) were incubated for 30 minutes at 28°C with solutions of buffer, unfractionated heparin or fondaparinux (20 μL), and HIT sera (40 μL). Then, 10 μL of these samples was added into tubes containing HEPES buffer (90 μL) and fluorescein isothiocyanate (FITC)–PAC1 monoclonal antibody or phycoerythrin (PE)– anti-CD62 monoclonal antibody or FITC-annexin V, (Becton Dickinson, San Jose, CA). The binding of PAC1 monoclonal antibody, anti-CD62 monoclonal antibody, and annexin V reflects the activation of glycoprotein (Gp) IIb-IIIa complex, the release of dense granules, and the expression of negatively charged phospholipids, respectively.22-24 After a 15-minute incubation at room temperature and in the dark, the samples were diluted in 400 μL fixative solution (CellFIX, Becton Dickinson) and analyzed with a flow cytometer (Becton Dickinson FACScalibur). Analyses were performed on 5000 events with the CellQuest program (Becton Dickinson). A threshold of positive events was set up to measure less than 2% of positive events in the blank sample. Results were expressed as the percentage of positive events, defined as events above the threshold. A threshold for positive activity was determined for each individual data. The model was fitted using the Generalized Linear Model function of the S-Plus 2000 software package in the PC/Windows 98 environment.28 Given the expression of the model and the estimates of , 1, and 2, it was possible to estimate the threshold level of stimulation with a 99% probability of successful stimulation.
Statistical analysis
The statistical analysis was performed using a logit model, assuming the binomial distribution of the response, including the 3 assays (SRA, HIPA, and platelet aggregation) and treatments (unfractionated heparin and fondaparinux) as fix factors.
Results
Characterization of the sera
Sera were collected from 15 healthy subjects without HIT and 45 patients with documented HIT. The reference laboratory reported that SRA was negative in all 15 sera obtained from healthy subjects and none contained antibodies to heparin-platelet 4 complex. SRA was negative in 6 of the 45 sera collected from patients with HIT. All the 39 remaining HIT sera gave positive results.
Control sera
Using SRA at another reference laboratory, one control serum (6.7%) was positive with 0.1 IU/mL unfractionated heparin; all other sera were negative, regardless of the compound tested (Table 1). Using HIPA, all control sera were negative with unfractionated heparin or fondaparinux. Platelet aggregation results were indeterminate with 4 sera (26.7%), platelets aggregating with 100 IU/mL unfractionated heparin. Of 11 remaining sera, platelet aggregation was positive with one control serum (9.1%) in the presence of 0.3 IU/mL unfractionated heparin.
HIT sera
The results of the 3 types of platelet assays for heparin-dependent antiplatelet antibodies on the sera obtained from 39 patients with HIT in the presence of buffer or various concentrations of unfractionated heparin or fondaparinux are shown in Tables 1 and 2.
SRA. SRA results were indeterminate for 5 HIT sera, leaving 34 evaluable sera. SRA was positive in 26 of these sera (76.5%) with unfractionated heparin, but only in 2 sera with fondaparinux (5.9%). Interestingly, one serum testing positive with fondaparinux (serum no. 24) was negative with unfractionated heparin. In addition, the mean percentage of maximum serotonin release obtained with unfractionated heparin was 65.7% (n = 26; range, 25%-100%) as compared to 33.5% with fondaparinux (n = 2; 39% and 28%).
HIPA. HIPA results were indeterminate for 3 HIT sera, leaving 36 evaluable sera. Of those 33 sera (91.7%) were positive with unfractionated heparin at low but not at high concentrations (100 IU/mL).
Of these 33 sera, 16 were negative with buffer and 17 reacted weakly with platelets without addition of heparin or fondaparinux. This reaction was strongly enhanced by heparin but not by fondaparinux with respect to the concentrations tested. However, the very high concentration of fondaparinux (100 μg/mL) inhibited the heparin-independent platelet-activating effect of HIT antibodies in 9 of 17 sera. These weak reactions in the absence of heparin might be due to unknown antibodies or platelet-activating agents in patient sera, not related to HIT. Alternatively they may be HIT antibodies giving a weak positive reaction because of contamination with traces of heparin. The effect of fondaparinux occurs only at high concentration and does not seem to be relevant for its anti-Xa activity. Of the 16 sera not showing any platelet-activating effect in the presence of buffer, 15 did not cause platelet activation in the presence of any of the fondaparinux concentrations tested. One serum showed a weak platelet activating effect in the presence of fondaparinux.
Platelet aggregation. Platelet aggregation was not done in 6 samples due to insufficient amount of serum. The result was indeterminate with 9 HIT sera, leaving 24 evaluable sera. The test was positive in 16 sera (66.7%) with unfractionated heparin and in none with fondaparinux.
Statistical analysis. With fondaparinux, the overall level of positive activity (without distinction of the methods) in the presence of HIT sera (3.3%, 3 of 91) was not different from that in the presence of control sera (0.0%, 0 of 41, P = .91). In contrast, with unfractionated heparin, the overall level of positive activity was significantly (P < .001) greater in the presence of HIT sera (75 of 94, 79.8%) than in the presence of control sera (2 of 41, 4.9%). In addition, in the presence of HIT sera, the level of positive activity was significantly (P < .001) greater with unfractionated heparin than with fondaparinux (79.8% versus 3.3%, respectively).
Flow cytometry analysis
The results of the binding of PAC1 and anti-CD62 monoclonal antibodies or annexin V to the platelets in the presence of 14 HIT sera and various concentrations of unfractionated heparin and fondaparinux are shown in Table 3.
PAC1 is a monoclonal antibody that recognizes the active conformation of human GpIIb-IIIa present at the platelet surface. The activation of GpIIb-IIIa is clearly correlated to the ability of the complex to bind soluble fibrinogen and result in platelet aggregation.29
CD62 is an intraplatelet protein that is not present on the surface of resting platelets. It is stored in the membrane of the granules and is exposed when these granules fuse with the external membrane. It can therefore be considered as a marker of platelet release.30
Annexin V is a positively charged protein, which binds to electronegative phospholipids such as phosphatidyl-serine. It is currently used as a probe for measuring the exposure of electronegative phospholipids allowing the platelet surface to trigger thrombin generation.31
Using unfractionated heparin, the mean binding of PAC1 and anti-CD62 monoclonal antibodies or annexin V increased according to a bell-shaped dose-effect curve; the binding was maximum with 0.3 and 1 IU/mL and negligible with 100 IU/mL. Platelet activation, according to a threshold of positive activity threshold set for each individual HIT serum, in the presence of unfractionated heparin concentrations of 0.1, 0.3, or 1 IU/mL was observed with annexin V, PAC1 monoclonal antibody, and anti-CD62 monoclonal antibody in 14 (100%), 9 (64.3%, ie, all sera except nos. 4, 18, 32, 33, 39), and 13 (92.9%, ie, all sera except no.4) HIT sera, respectively. In contrast, in the presence of fondaparinux, the mean binding of annexin V, PAC1 monoclonal antibody, and anti-CD62 monoclonal antibody did not change, regardless of the fondaparinux concentration; none of the 14 HIT sera tested positive with fondaparinux, regardless of the fondaparinux concentration and the platelet activation membrane marker.
Discussion
Using 3 functional assays, our study shows that, in most cases, fondaparinux does not activate platelets in the presence of sera obtained from patients with HIT; the platelet aggregation test was negative with all evaluable sera, the HIPA test was positive with only one serum (3.0%), and the SRA was positive with only 5.9% of the HIT sera. In contrast, with unfractionated heparin, the results were positive with the 3 tests in approximately 67% to 92% of HIT sera. We suggest that our results are reliable for several reasons. First, the sera were carefully selected and characterized. Second, a combination of 3 reference complementary functional tests was used. Third, all control and HIT sera were investigated in a blinded manner using a large range of fondaparinux and unfractionated heparin concentrations. Furthermore, the inability of fondaparinux to activate platelets in the presence of HIT sera was confirmed by the flow cytometry analysis of GpIIb-IIIa activation, dense granule release, and expression of negatively charged phospholipids on the platelet membrane, 3 highly sensitive markers of platelet activation.
There is variability among different biologic assays in detecting the presence of heparin-dependent platelet antibodies. For this reason, we studied the ability of fondaparinux and unfractionated heparin to induce platelet activation in the presence of HIT sera using 3 reference functional assays. Compared to platelet aggregation performed in platelet-rich plasma, tests using washed platelets, for example, HIPA and SRA, are generally considered to be the more sensitive for detecting heparin-dependent platelet antibodies.
The generation of HIT-related antigen has been shown to be dependent on the molecular weight of polysaccharides, the optimal chain length being 16 saccharides.14 Fondaparinux, a pentasaccharide, may therefore be considered to be too small to induce the expression of such antibodies. Indeed, the present study confirms that fondaparinux does not appear to interact with HIT-related antibodies to induce platelet activation and aggregation. This result differentiates fondaparinux from low-molecular-weight heparins, which show complete cross-reactivity with the antibodies that cause HIT and which are known to exacerbate HIT in those patients with preformed antibodies.21 Overall, our results are consistent with the report that no episodes of HIT were reported in the phase 2 and phase 3 program of fondaparinux,4-13 notably in patients after major orthopedic surgery of the lower limbs, a setting at particularly high risk for developing HIT and thrombosis,32 in which fondaparinux was given to approximately 5000 patients.4-9 Moreover, some cases have been reported of successful treatment with fondaparinux in patients hypersensitive to heparin and low-molecular-weight heparin.33,34 In contrast, orthopedic patients treated with unfractionated heparin have about a 5% risk of HIT with at least half of the affected patients developing HIT-associated thrombosis; the HIT risk with low-molecular-weight heparins in this setting has been estimated as 0.75%.1
The inability of fondaparinux to induce platelet activation in the presence of HIT sera was demonstrated in previous smaller studies.14,15 We confirm this finding over a large range of fondaparinux concentrations using 3 complementary qualitative assays. Furthermore, using flow cytometry, we show that the addition of fondaparinux to HIT sera and platelets did not result in platelet activation as measured using annexin V, activation of GpIIb-IIIa, or the release of dense granules. Interestingly, among these 3 markers of platelet activation, annexin V was the most sensitive for detecting heparin-dependent platelet antibodies. The positivity of SRA with fondaparinux in 2 sera and of HIPA in one serum is of uncertain significance and its biologic relevance is uncertain; of note, serum no. 24 was not positive with unfractionated heparin and serum no. 33 was negative when the binding of annexin V was studied in the presence of fondaparinux on flow cytometry. A previous study showed that, in contrast to unfractionated heparin, fondaparinux did not increase the binding of HIT-related antibodies to purified platelet factor 4.16 The inability of fondaparinux to induce platelet activation in the presence of HIT may be related to the fact that this pentasaccharide does not have the minimal chain length and minimum charge per carbohydrate required for induction of the HIT antigen on platelet factor 4.14
Selection of patients with HIT, from whom serum was collected, was on the basis of both clinical and laboratory criteria, as recommended in a recent consensus report.21 HIT sera were defined by the presence of IgG antibodies to heparin-platelet factor 4 complex.35 The specificity of assays for heparin-dependent platelet activation was verified because samples were only categorized as positive if the positive results observed in the presence of clinically relevant heparin concentration were reversed in the presence of high concentrations of unfractionated heparin1; in the case of heparin-dependent platelet activation, high concentrations of unfractionated heparin displace the heparin-platelet factor 4 complex from the platelet surface and the test becomes negative.22
In conclusion, the safety of fondaparinux administration to patients in terms of HIT, which has yet to be firmly established clinically, may be an important advantage of fondaparinux over the heparins. Further, our study suggests that fondaparinux, which does not enhance the platelet activation effect of HIT sera, could be used as a treatment for HIT.
Appendix
Collection of the sera: B. H. Chong (Department of Haematology, Prince of Wales Hospital, Randwick, NSW, Australia), A. Greinacher (Universitt Greifswald, Greiswald, Germany), and Y. Gruel (Service d'Hematologie-Hemostase, hospital Trousseau, Tours, France); preparation of sera and of heparin and fondaparinux solutions: Sanofi-Synthelabo Recherche, Toulouse, France; characterization of sera: J. G. Kelton and T. W. Warkentin (Platelet Immunology Laboratory, Hamilton, ON, Canada); serotonin release assay: B. H. Chong; heparin-induced platelet agglutination: A. Greinacher; platelet aggregation: Y. Gruel; flow cytometry: P. Savi and J. M. Herbert (Sanofi-Synthelabo Recherche, Toulouse, France); and data collection: Sanofi-Synthelabo Recherche.
Footnotes
Prepublished online as Blood First Edition Paper, September 23, 2004; DOI 10.1182/blood-2004-05-2010.
Supported by a grant from Sanofi-Synthelabo and NV Organon. Studies performed in the laboratory of J.G.K. were supported by the Heart and Stroke Foundation of Ontario (Canada). The pharmaceutical research and development of fondaparinux (Arixtra) are being pursued within a partnership agreement between Sanofi-Synthelabo (France) and Organon (The Netherlands). P.S., D.M., M.P., J.P.H., R.C., and J.M.H. are employees of either Sanofi-Synthelabo or Organon.
An Inside Blood analysis of this article appears in the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
References
Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82: 439-447.
van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem [Int Ed Engl]. 1993;32: 1671-1690.
Herbert J-M, Petitou M, Lormeau J-C, et al. SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997;15: 1-26.
Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344: 619-625.
Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345: 1298-1304.
Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345: 1305-1310.
Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359: 1715-1720.
Turpie AGG, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359: 1721-1726.
Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163: 1337-1342.
The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation. 2000;102; 2726-2731.
MATISSE. Fondaparinux (Arixtra) in comparison to (low-molecular-weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism—The Matisse clinical outcome studies . Blood. 2002;100: 83a.
Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa-inhibitor (ORG31540SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J. 2001;22: 1716-1724.
Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81: 214-220.
Greinacher A, Alban S, Dummel S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirement for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74: 886-892.
Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost. 1995;74: 1384-1385.
Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR91107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997;8: 114-117.
Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost. 1999;5: 259-266.
Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67: 27-30.
Greinacher A, Michels I, Klefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66: 734-736.
Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69: 344-350.
Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79: 1-7.
Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87: 4925-4936.
Vitale M, Tazzari P, Ricci F, et al. Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry. 2001;46: 290-295.
Poley S, Mempel W. Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test. Eur J Haematol. 2001;66: 253-262.
Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996; 95: 161-167.
Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced platelet activation test (HIPA) in comparison with a PF4/Heparin ELISA. Thromb Haemost. 1999;81: 625-629.
Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahouse B, Gruel Y. Decision analysis for use of platelet aggregation test, 14C-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111: 700-706.
McCullagh P, Nelder JA. Generalized Linear Models. London, United Kingdom: Ed Chapman and Hall; 1983.
Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262: 992-1000.
Israels SJ, Gerrard JM, Jacques YV, et al. Platelet dense granule membranes contain both granulophysin and P-selectin (GMP-140). Blood. 1992;80: 143-152.
Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem. 1991;266: 24302-24307.
Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood. 2000;96: 1703-1708.
Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica. 2003;88: ECR32.
D'Amico EA, Villaca PR, Gualandro SF, Bassitt RP, Chamone DA. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1: 2452-2453.
Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res. 2002;105: 117-123.(Pierre Savi, Beng H. Chon)
Department of Medicine, St George Hospital, Kogarah, Australia
Department of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany
Service d'Hematologie-Hemostase, hospital Trousseau, Tours, France
Platelet Immunology Laboratory, McMaster University, Hamilton, ON, Canada
NV Organon, Oss, The Netherlands.
Abstract
Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy caused by antibodies against a complex of platelet factor 4 and heparin. Fondaparinux (Arixtra) is a new synthetic selective factor Xa inhibitor. We performed a serologic study to determine the cross-reactivity of HIT sera with fondaparinux. Using a prospective, blinded study design, 39 clinically and serologically confirmed sera from patients with HIT and 15 control sera were sent to 3 different laboratories, each of which specialized in a particular HIT assay. These include the serotonin release assay, heparin-induced platelet agglutination assay, and platelet aggregation assay. Two of 82 assays (2.4%) performed in the presence of control sera were positive, both with unfractionated heparin. In the presence of HIT sera, 75 of 94 (79.8%) evaluable assays were positive with unfractionated heparin; fondaparinux was significantly (P < .001) less reactive than unfractionated heparin, only 3 of 91 evaluable assays (3.3%) being positive. Using flow cytometry, unlike unfractionated heparin, fondaparinux did not induce the binding of PAC1 and anti-CD62 monoclonal antibodies or of annexin V to platelets with HIT sera. Together, these results suggest that fondaparinux is nonreactive to HIT sera and raise the possibility that the drug may be used for prophylaxis and treatment of thrombosis in patients with a history of HIT.
Introduction
Heparin-induced thrombocytopenia (HIT) is a rare but severe complication of heparin therapy.1 HIT is caused by heparin-dependent antibodies (typically IgG), which are directed against a molecular complex formed by heparin and the platelet -granule protein, platelet factor 4.1 These IgG immune complexes bind to the FcIIa receptors on the platelet surface, resulting in platelet activation and aggregation, and eventually, to the occurrence of both thrombocytopenia and thrombosis. For patients with HIT, treatment with heparin must be stopped and an alternative antithrombotic agent used. Low-molecular-weight heparins cannot be used because they also cross-react, although to a lesser extent, with HIT-associated antibodies.1
Fondaparinux, a new synthetic and selective inhibitor of coagulation factor Xa,2,3 has been shown to be an effective and safe antithrombotic agent in a number of thrombotic disorders.4-13 No episodes of HIT were reported in the large phase 2 and 3 clinical program. This result is consistent with the fact that, in vitro, fondaparinux did not cross-react with HIT-associated antibodies.14-17 However, these in vitro studies, using a limited set of sera and different methodologies of variable sensitivity and specificity, did not permit a definitive conclusion to be made regarding the safety of fondaparinux in terms of its ability to induce platelet activation in the presence of HIT-associated antibodies.
Currently, besides enzyme immunoassays that measure antibodies to heparin-platelet factor 4 complex, 3 functional assays are used in vitro to investigate the effect of HIT-associated antibodies on platelet function, namely, the serotonin release assay (SRA), considered to be the gold standard,18 the heparin-induced platelet agglutination assay (HIPA),19 and the platelet aggregation test.20 These biologic assays are difficult to perform and interpret.1,21 Additionally, there may be advantages in performing all assays together to further enhance sensitivity and specificity.21 Using these 3 assays, we compared in a blinded manner the effect of fondaparinux with that of unfractionated heparin on platelet activation and aggregation in the presence of sera collected from patients with clinically documented HIT. The effect of fondaparinux on platelet activation in the presence of HIT sera was further assessed using sensitive flow cytometry techniques to measure the expression of specific platelet activation-related markers on the platelet surface.22-24
Patients, materials, and methods
Study design
Sera from patients with laboratory-confirmed HIT (HIT sera) and from subjects without HIT (control sera) were collected in 3 centers (see "Appendix"). All the sera were then aliquoted and a subsample sent to a predetermined reference laboratory (see "Appendix") for characterization. This reference laboratory performed both enzyme immunoassays plus SRA on all of these samples to confirm positive or negative results. These independently verified sera were then sent to the central laboratory. The central laboratory then sent out the positive HIT sera and negative control sera, in a coded and blinded fashion, to the 3 participating test laboratories (see "Appendix"). All of the 3 test laboratories were also provided with solutions of buffer, unfractionated heparin, and fondaparinux for the serotonin release, platelet agglutination, and platelet aggregation assays. One specific assay was performed per center. All investigators were blinded about the type of serum and the type of test solution. All blood donors gave informed consent in accordance with the Declaration of Helsinki.
Sera
A first set of sera was obtained from 45 patients with a diagnosis of HIT. These patients had HIT defined by a fall in the platelet count to less than 100 x 109/L or a 50% decrease in platelet count, 5 or more days after starting heparin therapy. Other causes of thrombocytopenia (ie, autoimmune thrombocytopenia, secondary immune thrombocytopenia, drug-dependent thrombocytopenia, and infection-dependent thrombocytopenia) were excluded, according to clinical diagnosis. The HIT sera were all positive in the designated reference laboratory. A second set of sera was obtained from 15 healthy volunteers not receiving heparin or other agents known to affect the coagulation system. All sera collected from patients with HIT, positive on SRA, and confirmed to have antibodies against heparin-platelet factor 4 (HIT-IgG) by the reference laboratory, were categorized as "HIT serum." All sera collected from healthy subjects, negative on SRA and in which the absence of HIT-IgG was confirmed by the reference laboratory, were designated as "control serum." Before use, the sera were heated at 56°C for 30 minutes to inactivate complement and traces of thrombin. Except for confirmatory testing, the reference laboratory was not part of the laboratory testing.
Unfractionated heparin and fondaparinux
Solutions of various concentrations of unfractionated heparin (Sanofi-Synthelabo, Paris, France) and fondaparinux (Sanofi-Synthelabo, Toulouse, France, and Organon, Oss, The Netherlands) were prepared in saline and frozen until use. The final concentrations of unfractionated heparin and fondaparinux used in the different assays on platelet function were 0.1, 0.3, 1.0, and 100 IU/mL, and 0.1, 0.3, 1.0, 3.0, and 100 μg/mL, respectively.
Enzyme immunoassay for antibodies to heparin–platelet factor 4 complex
The presence of antibodies to heparin–platelet factor 4 complex (HIT-IgG) was investigated using an enzyme immunoassay described previously.25 Purified platelet factor 4 (20 μg/mL; R&D Systems, Lille, France) and unfractionated heparin (1 IU/mL; Organon Teknika, Toronto, ON, Canada) were incubated overnight at 4°C in carbonated buffer (50 mM NaHCO3/Na2CO3, pH 9.6) on a 96-well microtiter plate. The plate was then saturated with 10% normal goat serum (Santa Cruz Biotechnology, Heidelberg, Germany) in phosphate-buffered saline (PBS; pH 7.2) for 2 hours at room temperature. Test sera diluted in 2% normal goat serum in PBS were added, and the microtiter plate was incubated at room temperature for 1 hour. After washing, alkaline phosphatase-conjugated, goat Fc chain-specific antihuman IgG antibody (Jackson ImmunoResearch, West Grove, PA) was added to each well. After 1 hour of incubation and washing, p-nitrophenyl phosphate (1 mg/mL in diethanolamine buffer, 1 M, pH 9.6) was added, and the absorbance was read at 405 nm. The result was considered as positive when the optical density (OD) was more than 0.45.
Platelet activation assays for HIT-associated antibodies
SRA. The SRA was performed as previously described.18 Platelet-rich plasma, obtained by centrifugation (165g, 15 minutes) of whole blood collected in acid-citrate-dextrose (ACD; 1:6, vol/vol, pH 4.5) from healthy individuals who had not taken aspirin within the 7 days preceding blood collection, was incubated with 14C-serotonin (0.1 μCi [0.0037 MBq]/mL platelet-rich plasma; Amersham, Oakville, ON, Canada or Amersham, Little Chalfront, Buckinghamshire, United Kingdom) for 30 minutes at 37°C. Sera and solutions of buffer, unfractionated heparin, or fondaparinux were added to washed, radiolabeled platelets; the mixture was incubated with constant stirring or under gentle agitation at room temperature for 1 hour. The reaction was stopped by adding EDTA (ethylenediaminetetraacetic acid, 0.5%)/PBS buffer, and the amount of 14C-serotonin released into the supernatant was measured using a scintillation counter after centrifugation (1800g, 5 minutes). The result was considered as "positive" with unfractionated heparin when the release of 14C-serotonin was more than 20% at 0.1, 0.3, or 1 IU/mL unfractionated heparin and less than 20% at 100 IU/mL unfractionated heparin. For fondaparinux, a result was considered as "positive" when the release was more than 20% at 0.1, 0.3, 1.0, or 3.0 μg/mL fondaparinux and less than 20% at 100 μg/mL fondaparinux. If the release was more than 20% in the presence of buffer, 100 IU/mL unfractionated heparin, or 100 μg/mL fondaparinux, the result was considered as "indeterminate." In all other cases, the result was considered as "negative." The "positive" results obtained with SRA at 0.1 IU/mL and 0.3 IU/mL unfractionated heparin were only considered true positive if they could be confirmed by suppression with anti-FcIIa receptor antibodies (10 μg/mL, American Type Culture Collection, Rockville, MD).
HIPA. HIPA was performed as previously described.26 Platelet-rich plasma was prepared by centrifugation (120g, 20 minutes) from citrated blood (ACD; 1.6:8.4, vol/vol) from healthy donors who had not taken any medication within the previous 10 days. Apyrase (grade IV, 5 μL at 1000 U/mL; Sigma, Munich, Germany) was added, and platelets were washed and resuspended in Tyrode buffer (pH 6.3) containing 2.5 U/mL apyrase and 1 U/mL hirudin (Pentapharm, Basel, Switzerland). After incubation in sealed tubes at 37°C for 15 minutes, platelets were centrifuged (650g, 7 minutes), resuspended to obtain a platelet concentration of 300 to 400 x 109/L in 1 mL suspension buffer (Tyrode buffer, 0.212 M MgCl2, 0.196 M CaCl2, pH 7.2), and incubated in a sealed tube at 37°C for 45 minutes before use. Sera (20 μL), solutions of buffer, unfractionated heparin or fondaparinux (10 μL), and platelet suspension (75 μL) were dispensed into a microtiter plate that contained 2 steel spheres, and further incubated at room temperature on a magnetic stirrer for 45 minutes. The transparency of the solution was assessed every 5 minutes using an indirect light source. Duplicate experiments were performed for each platelet suspension. Each serum was tested with platelets from 4 different platelet donors. For unfractionated heparin, the result was considered as "positive" if the suspension became transparent due to platelet agglutination with 0.1, 0.3, or 1 IU/mL unfractionated heparin, but not or only weakly and with a significant delay with buffer and 100 IU/mL unfractionated heparin, for at least 2 of the 4 platelet donors. For fondaparinux, the result was "positive" if the suspension became transparent with 0.1, 0.3, 1.0, or 3.0 μg/mL fondaparinux, for at least 2 of the 4 platelet donors. If platelet agglutination occurred in the presence of 100 IU/mL unfractionated heparin for at least 2 of the 4 platelet donors, the result was considered as "indeterminate." In all other cases, the result was considered as "negative."
Platelet aggregation. Platelet aggregation was performed as previously described.27 Platelet-rich plasma, obtained by centrifugation (150g, 10 minutes) of whole blood collected in citrate (0.129 M, 1:9, vol/vol) from healthy individuals who had not taken aspirin within the 7 days preceding blood collection, was adjusted to 300 x 109/L. Platelet aggregation was measured at 37°C using an aggregometer (Platelet Aggregation Profiler; BioData, Horsham, PA). The ability of donor platelets to aggregate was first tested in the presence of collagen (70 μg/mL, Stago, Asnières, France). Then, platelet-rich plasma was incubated with sera and solutions of buffer, unfractionated heparin, or fondaparinux. Aggregation was considered as "positive" when it exhibited a sharp initial slope ( 20%/min) and a maximum level of aggregation of 50% or more within 20 minutes. For unfractionated heparin, the result was considered as "positive" when platelet aggregation occurred with 0.1, 0.3, or 1 IU/mL unfractionated heparin, but not with 100 IU/mL unfractionated heparin. For fondaparinux, the result was "positive" when platelet aggregation occurred at 0.1, 0.3, 1.0, or 3.0 μg/mL fondaparinux, but not with 100 μg/mL fondaparinux. If platelet aggregation occurred in the presence of buffer, 100 IU/mL unfractionated heparin, or 100 μg/mL fondaparinux, the result was considered as "indeterminate." In all other cases, the result was considered as "negative," but before concluding the result was negative, platelet-rich plasma from at least 2 different donors was tested.
Flow cytometry analysis
Platelet-rich plasma was prepared by centrifugation (100g, 5 minutes) from citrated blood (citrate 0.129 M, 1:9, vol/vol) from healthy individuals to which was added 180 μL acidifying buffer/1 mL platelet-rich plasma. Acidifying buffer contained 75 mM trisodium citrate dehydrate, 38 mM citric acid monohydrate, 140 mM dextrose, and prostacyclin (12 ng/mL final, Sigma). Platelets were washed and resuspended in HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer containing 134 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.34 mM Na2PHO4, 1 mM MgCl2, 5 mM glucose, 5 mM HEPES, and 0.35% bovine serum albumin (pH 7.4). Platelet suspension samples (140 μL) were incubated for 30 minutes at 28°C with solutions of buffer, unfractionated heparin or fondaparinux (20 μL), and HIT sera (40 μL). Then, 10 μL of these samples was added into tubes containing HEPES buffer (90 μL) and fluorescein isothiocyanate (FITC)–PAC1 monoclonal antibody or phycoerythrin (PE)– anti-CD62 monoclonal antibody or FITC-annexin V, (Becton Dickinson, San Jose, CA). The binding of PAC1 monoclonal antibody, anti-CD62 monoclonal antibody, and annexin V reflects the activation of glycoprotein (Gp) IIb-IIIa complex, the release of dense granules, and the expression of negatively charged phospholipids, respectively.22-24 After a 15-minute incubation at room temperature and in the dark, the samples were diluted in 400 μL fixative solution (CellFIX, Becton Dickinson) and analyzed with a flow cytometer (Becton Dickinson FACScalibur). Analyses were performed on 5000 events with the CellQuest program (Becton Dickinson). A threshold of positive events was set up to measure less than 2% of positive events in the blank sample. Results were expressed as the percentage of positive events, defined as events above the threshold. A threshold for positive activity was determined for each individual data. The model was fitted using the Generalized Linear Model function of the S-Plus 2000 software package in the PC/Windows 98 environment.28 Given the expression of the model and the estimates of , 1, and 2, it was possible to estimate the threshold level of stimulation with a 99% probability of successful stimulation.
Statistical analysis
The statistical analysis was performed using a logit model, assuming the binomial distribution of the response, including the 3 assays (SRA, HIPA, and platelet aggregation) and treatments (unfractionated heparin and fondaparinux) as fix factors.
Results
Characterization of the sera
Sera were collected from 15 healthy subjects without HIT and 45 patients with documented HIT. The reference laboratory reported that SRA was negative in all 15 sera obtained from healthy subjects and none contained antibodies to heparin-platelet 4 complex. SRA was negative in 6 of the 45 sera collected from patients with HIT. All the 39 remaining HIT sera gave positive results.
Control sera
Using SRA at another reference laboratory, one control serum (6.7%) was positive with 0.1 IU/mL unfractionated heparin; all other sera were negative, regardless of the compound tested (Table 1). Using HIPA, all control sera were negative with unfractionated heparin or fondaparinux. Platelet aggregation results were indeterminate with 4 sera (26.7%), platelets aggregating with 100 IU/mL unfractionated heparin. Of 11 remaining sera, platelet aggregation was positive with one control serum (9.1%) in the presence of 0.3 IU/mL unfractionated heparin.
HIT sera
The results of the 3 types of platelet assays for heparin-dependent antiplatelet antibodies on the sera obtained from 39 patients with HIT in the presence of buffer or various concentrations of unfractionated heparin or fondaparinux are shown in Tables 1 and 2.
SRA. SRA results were indeterminate for 5 HIT sera, leaving 34 evaluable sera. SRA was positive in 26 of these sera (76.5%) with unfractionated heparin, but only in 2 sera with fondaparinux (5.9%). Interestingly, one serum testing positive with fondaparinux (serum no. 24) was negative with unfractionated heparin. In addition, the mean percentage of maximum serotonin release obtained with unfractionated heparin was 65.7% (n = 26; range, 25%-100%) as compared to 33.5% with fondaparinux (n = 2; 39% and 28%).
HIPA. HIPA results were indeterminate for 3 HIT sera, leaving 36 evaluable sera. Of those 33 sera (91.7%) were positive with unfractionated heparin at low but not at high concentrations (100 IU/mL).
Of these 33 sera, 16 were negative with buffer and 17 reacted weakly with platelets without addition of heparin or fondaparinux. This reaction was strongly enhanced by heparin but not by fondaparinux with respect to the concentrations tested. However, the very high concentration of fondaparinux (100 μg/mL) inhibited the heparin-independent platelet-activating effect of HIT antibodies in 9 of 17 sera. These weak reactions in the absence of heparin might be due to unknown antibodies or platelet-activating agents in patient sera, not related to HIT. Alternatively they may be HIT antibodies giving a weak positive reaction because of contamination with traces of heparin. The effect of fondaparinux occurs only at high concentration and does not seem to be relevant for its anti-Xa activity. Of the 16 sera not showing any platelet-activating effect in the presence of buffer, 15 did not cause platelet activation in the presence of any of the fondaparinux concentrations tested. One serum showed a weak platelet activating effect in the presence of fondaparinux.
Platelet aggregation. Platelet aggregation was not done in 6 samples due to insufficient amount of serum. The result was indeterminate with 9 HIT sera, leaving 24 evaluable sera. The test was positive in 16 sera (66.7%) with unfractionated heparin and in none with fondaparinux.
Statistical analysis. With fondaparinux, the overall level of positive activity (without distinction of the methods) in the presence of HIT sera (3.3%, 3 of 91) was not different from that in the presence of control sera (0.0%, 0 of 41, P = .91). In contrast, with unfractionated heparin, the overall level of positive activity was significantly (P < .001) greater in the presence of HIT sera (75 of 94, 79.8%) than in the presence of control sera (2 of 41, 4.9%). In addition, in the presence of HIT sera, the level of positive activity was significantly (P < .001) greater with unfractionated heparin than with fondaparinux (79.8% versus 3.3%, respectively).
Flow cytometry analysis
The results of the binding of PAC1 and anti-CD62 monoclonal antibodies or annexin V to the platelets in the presence of 14 HIT sera and various concentrations of unfractionated heparin and fondaparinux are shown in Table 3.
PAC1 is a monoclonal antibody that recognizes the active conformation of human GpIIb-IIIa present at the platelet surface. The activation of GpIIb-IIIa is clearly correlated to the ability of the complex to bind soluble fibrinogen and result in platelet aggregation.29
CD62 is an intraplatelet protein that is not present on the surface of resting platelets. It is stored in the membrane of the granules and is exposed when these granules fuse with the external membrane. It can therefore be considered as a marker of platelet release.30
Annexin V is a positively charged protein, which binds to electronegative phospholipids such as phosphatidyl-serine. It is currently used as a probe for measuring the exposure of electronegative phospholipids allowing the platelet surface to trigger thrombin generation.31
Using unfractionated heparin, the mean binding of PAC1 and anti-CD62 monoclonal antibodies or annexin V increased according to a bell-shaped dose-effect curve; the binding was maximum with 0.3 and 1 IU/mL and negligible with 100 IU/mL. Platelet activation, according to a threshold of positive activity threshold set for each individual HIT serum, in the presence of unfractionated heparin concentrations of 0.1, 0.3, or 1 IU/mL was observed with annexin V, PAC1 monoclonal antibody, and anti-CD62 monoclonal antibody in 14 (100%), 9 (64.3%, ie, all sera except nos. 4, 18, 32, 33, 39), and 13 (92.9%, ie, all sera except no.4) HIT sera, respectively. In contrast, in the presence of fondaparinux, the mean binding of annexin V, PAC1 monoclonal antibody, and anti-CD62 monoclonal antibody did not change, regardless of the fondaparinux concentration; none of the 14 HIT sera tested positive with fondaparinux, regardless of the fondaparinux concentration and the platelet activation membrane marker.
Discussion
Using 3 functional assays, our study shows that, in most cases, fondaparinux does not activate platelets in the presence of sera obtained from patients with HIT; the platelet aggregation test was negative with all evaluable sera, the HIPA test was positive with only one serum (3.0%), and the SRA was positive with only 5.9% of the HIT sera. In contrast, with unfractionated heparin, the results were positive with the 3 tests in approximately 67% to 92% of HIT sera. We suggest that our results are reliable for several reasons. First, the sera were carefully selected and characterized. Second, a combination of 3 reference complementary functional tests was used. Third, all control and HIT sera were investigated in a blinded manner using a large range of fondaparinux and unfractionated heparin concentrations. Furthermore, the inability of fondaparinux to activate platelets in the presence of HIT sera was confirmed by the flow cytometry analysis of GpIIb-IIIa activation, dense granule release, and expression of negatively charged phospholipids on the platelet membrane, 3 highly sensitive markers of platelet activation.
There is variability among different biologic assays in detecting the presence of heparin-dependent platelet antibodies. For this reason, we studied the ability of fondaparinux and unfractionated heparin to induce platelet activation in the presence of HIT sera using 3 reference functional assays. Compared to platelet aggregation performed in platelet-rich plasma, tests using washed platelets, for example, HIPA and SRA, are generally considered to be the more sensitive for detecting heparin-dependent platelet antibodies.
The generation of HIT-related antigen has been shown to be dependent on the molecular weight of polysaccharides, the optimal chain length being 16 saccharides.14 Fondaparinux, a pentasaccharide, may therefore be considered to be too small to induce the expression of such antibodies. Indeed, the present study confirms that fondaparinux does not appear to interact with HIT-related antibodies to induce platelet activation and aggregation. This result differentiates fondaparinux from low-molecular-weight heparins, which show complete cross-reactivity with the antibodies that cause HIT and which are known to exacerbate HIT in those patients with preformed antibodies.21 Overall, our results are consistent with the report that no episodes of HIT were reported in the phase 2 and phase 3 program of fondaparinux,4-13 notably in patients after major orthopedic surgery of the lower limbs, a setting at particularly high risk for developing HIT and thrombosis,32 in which fondaparinux was given to approximately 5000 patients.4-9 Moreover, some cases have been reported of successful treatment with fondaparinux in patients hypersensitive to heparin and low-molecular-weight heparin.33,34 In contrast, orthopedic patients treated with unfractionated heparin have about a 5% risk of HIT with at least half of the affected patients developing HIT-associated thrombosis; the HIT risk with low-molecular-weight heparins in this setting has been estimated as 0.75%.1
The inability of fondaparinux to induce platelet activation in the presence of HIT sera was demonstrated in previous smaller studies.14,15 We confirm this finding over a large range of fondaparinux concentrations using 3 complementary qualitative assays. Furthermore, using flow cytometry, we show that the addition of fondaparinux to HIT sera and platelets did not result in platelet activation as measured using annexin V, activation of GpIIb-IIIa, or the release of dense granules. Interestingly, among these 3 markers of platelet activation, annexin V was the most sensitive for detecting heparin-dependent platelet antibodies. The positivity of SRA with fondaparinux in 2 sera and of HIPA in one serum is of uncertain significance and its biologic relevance is uncertain; of note, serum no. 24 was not positive with unfractionated heparin and serum no. 33 was negative when the binding of annexin V was studied in the presence of fondaparinux on flow cytometry. A previous study showed that, in contrast to unfractionated heparin, fondaparinux did not increase the binding of HIT-related antibodies to purified platelet factor 4.16 The inability of fondaparinux to induce platelet activation in the presence of HIT may be related to the fact that this pentasaccharide does not have the minimal chain length and minimum charge per carbohydrate required for induction of the HIT antigen on platelet factor 4.14
Selection of patients with HIT, from whom serum was collected, was on the basis of both clinical and laboratory criteria, as recommended in a recent consensus report.21 HIT sera were defined by the presence of IgG antibodies to heparin-platelet factor 4 complex.35 The specificity of assays for heparin-dependent platelet activation was verified because samples were only categorized as positive if the positive results observed in the presence of clinically relevant heparin concentration were reversed in the presence of high concentrations of unfractionated heparin1; in the case of heparin-dependent platelet activation, high concentrations of unfractionated heparin displace the heparin-platelet factor 4 complex from the platelet surface and the test becomes negative.22
In conclusion, the safety of fondaparinux administration to patients in terms of HIT, which has yet to be firmly established clinically, may be an important advantage of fondaparinux over the heparins. Further, our study suggests that fondaparinux, which does not enhance the platelet activation effect of HIT sera, could be used as a treatment for HIT.
Appendix
Collection of the sera: B. H. Chong (Department of Haematology, Prince of Wales Hospital, Randwick, NSW, Australia), A. Greinacher (Universitt Greifswald, Greiswald, Germany), and Y. Gruel (Service d'Hematologie-Hemostase, hospital Trousseau, Tours, France); preparation of sera and of heparin and fondaparinux solutions: Sanofi-Synthelabo Recherche, Toulouse, France; characterization of sera: J. G. Kelton and T. W. Warkentin (Platelet Immunology Laboratory, Hamilton, ON, Canada); serotonin release assay: B. H. Chong; heparin-induced platelet agglutination: A. Greinacher; platelet aggregation: Y. Gruel; flow cytometry: P. Savi and J. M. Herbert (Sanofi-Synthelabo Recherche, Toulouse, France); and data collection: Sanofi-Synthelabo Recherche.
Footnotes
Prepublished online as Blood First Edition Paper, September 23, 2004; DOI 10.1182/blood-2004-05-2010.
Supported by a grant from Sanofi-Synthelabo and NV Organon. Studies performed in the laboratory of J.G.K. were supported by the Heart and Stroke Foundation of Ontario (Canada). The pharmaceutical research and development of fondaparinux (Arixtra) are being pursued within a partnership agreement between Sanofi-Synthelabo (France) and Organon (The Netherlands). P.S., D.M., M.P., J.P.H., R.C., and J.M.H. are employees of either Sanofi-Synthelabo or Organon.
An Inside Blood analysis of this article appears in the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
References
Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82: 439-447.
van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem [Int Ed Engl]. 1993;32: 1671-1690.
Herbert J-M, Petitou M, Lormeau J-C, et al. SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997;15: 1-26.
Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344: 619-625.
Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345: 1298-1304.
Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345: 1305-1310.
Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359: 1715-1720.
Turpie AGG, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359: 1721-1726.
Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163: 1337-1342.
The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation. 2000;102; 2726-2731.
MATISSE. Fondaparinux (Arixtra) in comparison to (low-molecular-weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism—The Matisse clinical outcome studies . Blood. 2002;100: 83a.
Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa-inhibitor (ORG31540SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J. 2001;22: 1716-1724.
Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81: 214-220.
Greinacher A, Alban S, Dummel S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirement for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74: 886-892.
Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost. 1995;74: 1384-1385.
Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR91107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997;8: 114-117.
Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost. 1999;5: 259-266.
Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67: 27-30.
Greinacher A, Michels I, Klefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66: 734-736.
Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69: 344-350.
Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79: 1-7.
Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87: 4925-4936.
Vitale M, Tazzari P, Ricci F, et al. Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry. 2001;46: 290-295.
Poley S, Mempel W. Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test. Eur J Haematol. 2001;66: 253-262.
Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996; 95: 161-167.
Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced platelet activation test (HIPA) in comparison with a PF4/Heparin ELISA. Thromb Haemost. 1999;81: 625-629.
Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahouse B, Gruel Y. Decision analysis for use of platelet aggregation test, 14C-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111: 700-706.
McCullagh P, Nelder JA. Generalized Linear Models. London, United Kingdom: Ed Chapman and Hall; 1983.
Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262: 992-1000.
Israels SJ, Gerrard JM, Jacques YV, et al. Platelet dense granule membranes contain both granulophysin and P-selectin (GMP-140). Blood. 1992;80: 143-152.
Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem. 1991;266: 24302-24307.
Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood. 2000;96: 1703-1708.
Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica. 2003;88: ECR32.
D'Amico EA, Villaca PR, Gualandro SF, Bassitt RP, Chamone DA. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1: 2452-2453.
Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res. 2002;105: 117-123.(Pierre Savi, Beng H. Chon)